Abstract
Mbd4 (methyl-binding domain 4) has been shown to be mutated in a high percentage of mismatch repair (MMR)-deficient colorectal tumours that exhibit microsatellite instability (MSI). However, the significance of these mutations is still unclear as they are predominantly monoallelic and the majority occur at a poly-A tract. Apart from MMR-deficient tumours, no other reports of mutations of Mbd4 in human neoplasia are as yet published. To address the significance of loss of Mbd4 in the absence of MMR, we have crossed Mbd4-deficient mice to mice lacking DNA MMR. We show that, in the context of MMR deficiency, additional loss of Mbd4 does not alter spontaneous mutation frequency at the endogenous Dlb-1b locus, nor does it modify tumour onset, tumour spectrum or MSI compared to singly mutant Msh2 or Mlh1 mice. Taken together, these findings show that nullizygosity or heterozygosity for Mbd4 does not affect MMR-dependent tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bacon AL, Farrington SM and Dunlop MG . (2000). Hum. Mol. Genet., 9, 2707–2713.
Bader S, Walker M and Harrison D . (2000). Br. J. Cancer, 83, 1646–1649.
Bader S, Walker M, Heindrich B, Bird A, Bird C, Hooper M and Wyllie A . (1999). Oncogene, 18, 8044–8047.
Bellacosa A, Cicchillitti L, Schepis F, Riccio A, Yeung AT, Matsumoto Y, Golemis EA, Genuardi M and Neri G . (1999). Proc. Natl. Acad. Sci. USA, 96, 3969–3975.
Buermeyer AB, Deschennes SM, Baker SM and Liskay RM . (1999). Annu. Rev. Genet., 33, 533–564.
Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L and Bellacosa A . (2003). Proc. Natl. Acad. Sci. USA, 100, 15071–15076.
Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T and Fishel R . (1997). Nat. Genet., 17, 114–118.
Drummond JT and Bellacosa A . (2001). Nucleic Acid Res., 29, 2234–2243.
Hendrich B and Bird A . (1998). Mol. Cell. Biol, 18, 6538–6547.
Hendrich B, Hardeland U, Ng HH, Jiricny J and Bird A . (1999). Nature, 401, 301–304.
Kongkanuntn R, Bubb VJ, Sansom OJ, Wyllie AH, Harrison DJ and Clarke AR . (1999). Oncogene, 18, 7219–7225.
Millar CB, Guy J, Sansom OJ, Selfridge J, MacDougall E, Hendrich B, Keightley PD, Bishop SM, Clarke AR and Bird A . (2002). Science, 297, 403–405.
Prolla TA, Baker SM, Harris AC, Tsao EL, Yao X, Bronner CE, Zheng BH, Gordon M, Reneker J, Arnheim N, Shibata D, Bradley A and Liskay RM . (1998). Nat. Genet., 18, 276–279.
Riccio A, Aaltonen LA, Godwin AK, Loukola A, Percesepe A, Salovaara R, Masciullo V, Genuardi M, Paravatou-Petsotas M, Bassi DE, Ruggeri BA, Klein-Szanto AJP, Testa JR, Neri G and Bellacosa A . (1999). Nat. Genet., 23, 266–268.
Sansom OJ, Bishop SM, Court H, Liskay RM and Clarke AR . (2003a). DNA Repair, 2, 1029–1039.
Sansom OJ and Clarke AR . (2000). Mutat. Res. – Fundam. Mol. Mech. Mutagen., 452, 149–162.
Sansom OJ, Stark LA, Dunlop MG and Clarke AR . (2001). Cancer Res., 61, 7060–7064.
Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A and Clarke AR . (2003b). Oncogene, 22, 7130–7136.
Screaton RA, Kiessling S, Sansom OJ, Millar CB, Maddison K, Bird A, Clarke AR and Frisch SM . (2003). Proc. Natl. Acad. Sci. USA, 100, 5211–5216.
Toft NJ, Curtis LJ, Sansom OJ, Leitch AL, Wyllie AH, te Riele H, Arends MJ and Clarke AR . (2002). Oncogene, 21, 6299–6306.
Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, te Riele H, Arends MJ, Wyllie AH, Margison GP and Clarke AR . (1999). Proc. Natl. Acad. Sci. USA, 96, 3911–3915.
Winton DJ, Blount MA and Ponder BA . (1988). Nature, 333, 463–466.
Wong E, Yang K, Kuraguchi M, Werling U, Avdievich E, Fan K, Fazzari M, Jin B, Brown AM, Lipkin M and Edelmann W . (2002). Proc. Natl. Acad. Sci. USA, 99, 14937–14942.
Acknowledgements
This work was supported by CR-UK, The Wales Gene Park and the Wellcome Trust. We thank Michael Liskay for supply of the Mlh1-deficient mice and Nathan Hill for maintenance of animal stocks.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sansom, O., Bishop, S., Bird, A. et al. MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR. Oncogene 23, 5693–5696 (2004). https://doi.org/10.1038/sj.onc.1207767
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207767
Keywords
This article is cited by
-
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Signal Transduction and Targeted Therapy (2019)
-
A human cancer-associated truncation of MBD4 causes dominant negative impairment of DNA repair in colon cancer cells
British Journal of Cancer (2007)
-
Mechanisms of Disease: methyl-binding domain proteins as potential therapeutic targets in cancer
Nature Clinical Practice Oncology (2007)